Synergo for Bladder Cancer

10/09/2025

For patients with recurrent or high-risk NMIBC, the treatment journey is often marked by uncertainty.
Synergo therapy is designed to deliver:
✅ A minimally invasive, outpatient procedure
✅ Preservation of the bladder
✅ Improved quality of life through fewer recurrences
Every patient should have access to treatments that address the cancer while also supporting quality of life after diagnosis.

08/09/2025

Standard intravesical chemotherapy faces well-known challenges: recurrence and progression rates remain high.
Synergo therapy integrates intravesical chemotherapy with radiofrequency-induced hyperthermia.
Clinical studies demonstrate:
🟡 Reduced recurrence rates
🟡 Longer disease-free intervals
🟡 A bladder-sparing approach for high-risk NMIBC patients
Learn how Synergo therapy is reshaping the future of bladder cancer treatment.

22/05/2025

Excited to be part of the 51st Annual Meeting of the Austrian Society of Urology and Andrology and the Bavarian Urological Association, starting today!

We’re looking forward to insightful discussions and meaningful connections over the coming days. If you’re attending, we warmly invite you to visit us – we’d be happy to connect and exchange ideas!

Heute startet die 51. Tagung der Österreichischen Gesellschaft für Urologie und Andrologie sowie der Bayerischen Urologenvereinigung – wir freuen uns sehr, dabei zu sein!

Wir erwarten spannende Vorträge, inspirierende Gespräche und den Austausch mit Kolleg:innen aus dem Fach. Besuchen Sie uns gerne vor Ort – wir freuen uns auf den persönlichen Kontakt und interessante Gespräche!

05/05/2025

May marks Bladder Cancer Awareness Month — an opportunity to raise awareness about a common, yet sometimes overlooked, disease.
Bladder cancer is the ninth most common cancer worldwide and the fourth most common in men. Men are affected four times more than women.
Over 600,000 new cases are diagnosed each year, and around 1.9 million people are currently living with the disease.

04/02/2025

Explore Synergo for NMIBC treatment. Maximize results with RF, chemo, and hyperthermia. Visit us at the upcoming EAU annual conference in Madrid!

11/04/2024

EAU annual conference was professional and well organized as always!! We hope you enjoyed it as much as we did and wish to thank all specialists from all over the world for expressing interest in the technology for and visiting our stand. We look forward to working with you soon.

10/01/2024

We would like to congratulate Urology Consultant Mr Ahmed Ali Alnaimi and his team at Frimley Health Trust UK, for their review update on NMIBC. We at Synergo feel privileged that our treatment modality is recognised as a leading therapeutic option in BCG-unresponsive NMIBC.

Bladder cancer encapsulates a wide spectrum of disease severities, with non-muscle invasive bladder cancer (NMIBC) representing an entirely different …

05/09/2023

A recent in vitro study finds that microwave treatment inhibits tumour cell proliferation and allows the natural apoptosis of HPV-infected cells to resume.
Microwave hyperthermia represses human papillomavirus oncoprotein activity and induces cell death due to cell stress in 3D tissue models of anogenital precancers and cancers - eBioMedicine (thelancet.com)

15/03/2023

Great professional and busy congress last weekend in Milan! We now have the time to thank all urology experts who visited us and dedicated their time to learn about RF technology for the treatment of bladder cancer.
We also wish to thank and for organizing this 38th EAU event.

21/02/2023

We look forward to seeing you at the upcoming EAU ! don't forget to visit us at booth A54 and hear about the latest clinical updates on Synergo.

09/02/2023

We wish to thank urology bladder cancer experts and participants for this great scientific event. the pathway for Synergo's cutting-Edge technology in the NHS.

02/01/2022

May the New Year bring you health, happiness, peace, and prosperity.